Programming Grants to Accompany NEH on the Road Exhibitions
Deadline : 9-26-2016
Funding Opportunity : RFA-CA-16-002
CFDA : 93.394|000000
Agency : Department of Health and Human Services
Contact : NIH OER Webmaster
This email address is being protected from spambots. You need JavaScript enabled to view it.
This email address is being protected from spambots. You need JavaScript enabled to view it.
Eligibility : State Governments
County Governments
City or Township Governments
Special District Governments
Independent School Districts
Public and State Controlled Institutions of Higher Education
Native American Tribal Governments (Federally recognized)
Public Housing Authorities/Indian Housing Authorities
Native American Tribal Organizations (other than Federally recognized tribal governments)
Nonprofits Having a 501 (c) (3) Status with the IRS (other than institutions of higher education)
Nonprofits that do not have a 501 (c) (3) status with the IRS (other than institutions of higher education)
Private institutions of higher education
For-profit organizations other than small business
Small businesses
Others
Details :
This Funding Opportunity Announcement (FOA) solicits grant applications proposing exploratory research projects focused on the advanced development of emerging molecular or cellular analysis technologies for basic or clinical cancer research. This FOA solicits R33 applications where proof-of-principle for the emerging technology or methodology has been provided with supportive preliminary data demonstrating a novel capability for targeting, probing, or assessing molecular and cellular features of cancer biology. Well-suited applications must offer the potential to accelerate and/or enhance research in the areas of cancer biology, early detection and screening, clinical diagnosis, treatment, control, epidemiology, and/or cancer health disparities. Technologies proposed for development may be intended to have widespread applicability but must be focused on improving molecular and/or cellular characterizations of cancer. Projects proposing to use established technologies where the novelty resides in the biological or clinical question being pursued are not appropriate for this solicitation and will not be reviewed.
